Journal: Cancer research
Article Title: NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction
doi: 10.1158/0008-5472.CAN-16-2204
Figure Lengend Snippet: DPP3 is overexpressed human breast cancer and correlates with increased NRF2 target gene expression and poor prognosis. (A) Box-and-whisker plots indicating the median score (horizontal line), the interquartile range (IQR, box boundaries) and 1.5 times the IQR (whiskers) demonstrate significantly higher DPP3 mRNA expression in 94 human breast tumors compared to 94 matched adjacent normal tissue samples (p=1.84×10-40, paired t-test). (B-C) A Spearman rank correlation demonstrating that DPP3 mRNA expression is positively correlated with DNA copy number status in (B) 1,031 TCGA breast tumor samples (p=1.6×10-96; r=0.5871) and (C) 1,992 samples from the METABRIC cohort (p=2.8×10-77, r=0.4019). (D) A Spearman rank correlation demonstrating that DPP3 and KEAP1 expression are positively correlated (p=7.6×10-11, r=0.2009) in the TCGA cohort. DPP3 expression is positively associated with NRF2 target gene expression (p=5.4×10-14, r=0.2314) despite a negative correlation with NRF2 mRNA expression (p=2.8×10-08, r= [-0.1719]). Tumors with mutations in DPP3, KEAP1, NRF2, FH and KRAS are indicated with vertical bars. (E) Similar results as in D were observed in the METABRIC cohort (n=1,992). Breast cancer samples in D and E are ranked based on DPP3 mRNA expression; high KEAP1, NRF2 and NRF2 target gene expression is shown in red while low expression is indicated in blue. (F-H) Kaplan-Meier plots comparing disease-specific survival in human breast tumors from the METABRIC cohort based on high (top quartile) versus low (bottom quartile) DPP3 expression in (F) all tumors, (G) ER+ tumors, or (H) ER- tumors. (I-K) Kaplan-Meier plots comparing disease-specific survival in human breast tumors from the METABRIC cohort based on high (top quartile) versus low (bottom quartile) NRF2 target gene expression in (I) all tumors, (J) ER+ tumors, or (K) ER- tumors.
Article Snippet: The primary antibodies used are as follows: anti-DPP3 rabbit monoclonal (ab133671, Abcam), anti-NQO1 mouse monoclonal (sc-32793, Santa Cruz), anti-NRF2 rabbit monoclonal (ab62352, Abcam), anti-KEAP1 goat polyclonal (E20, sc-15246, Santa Cruz), anti-β-Actin mouse monoclonal (sc-69879, Santa Cruz), anti-GAPDH rabbit polyclonal (sc-25778, Santa Cruz) and anti-p62 rabbit monoclonal (ab109012, Abcam).
Techniques: Expressing, Whisker Assay